# A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

> **NCT01268566** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 62 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** MEDI-575

## Key facts

- **NCT ID:** NCT01268566
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2017-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01268566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01268566, "A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01268566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*